Microfluidic system allows for rare single-cell enrichment, analysis and retrieval. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today the receipt of it first patent in China for the company’s single-cell capture system. The patent, “Cell Capture System and Method of Use”, applies to the company’s fundamental microfluidic technology for single-cell capture, analysis and […]

Read more

Microfluidic system allows for rare single-cell enrichment, analysis and retrieval Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products announced today the receipt of another patent for the company’s single-cell capture system. The patent, “Cell Capture System and Method of Use”, applies to the company’s fundamental microfluidic technology for single-cell capture, analysis and retrieval, and was […]

Read more

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech and medical device industries, has named Celsee Diagnostics as the Medical Device Company of the Year Trailblazer silver winner. “It was an honor to receive this award. Improved enumeration and molecular […]

Read more

“System for Imaging Captured Cells” was assigned U.S. Patent No. 9404864 Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products announced today the receipt of another patent. The patent, “System for Imaging Captured Cells”, applies to the Celsee ANALYZER imaging platform, and was assigned U.S. Patent No. 9404864 by the United States Patent and Trademark Office […]

Read more

Collaborative studies will determine the feasibility of using circulating tumor cells (CTCs) as a biospecimen for mutation analysis. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, and GENEWIZ, a global leader in R&D genomics services, announced today that they have entered into a collaboration to determine the feasibility of using circulating tumor cells (CTCs) as […]

Read more

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been selected as a 2016 Red Herring Top 100 North America winner. Red Herring Top 100 America enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the US and Canada. […]

Read more

Biotheranostics, a leader in molecular diagnostics for cancer, announced results from a study developing a functional workflow for gene expression profiling using blood samples, providing insights into the potential for circulating tumor cell-based cancer classification that may help reduce dependency on tissue specimens. The study was presented at the American Association for Cancer Research (AACR) […]

Read more

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been recognized as one of the 2016 “Michigan 50 Companies to Watch,” an awards program presented by Michigan Celebrates Small Business. Celsee Diagnostics will be honored at an awards ceremony during the twelfth annual Michigan Celebrates Small Business gala event, May […]

Read more

Celsee Diagnostics, an innovator of cutting-edge products of liquid biopsy, announces the publication of “Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples” in PLOS ONE. The peer-reviewed publication, developed in collaboration with The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, […]

Read more